Dyne therapeutics investors
WebApr 13, 2024 · Institutional and Insider Ownership. 12.1% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 11.5% of Nyxoah shares are held by … WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of 400,449.
Dyne therapeutics investors
Did you know?
WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... WebNov 3, 2024 · WALTHAM, Mass., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2024 and business …
WebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised to date? Dyne Therapeutics has raised $333M. When was the last funding round for Dyne Therapeutics? Dyne Therapeutics closed its last funding round on Jan 21, 2024 from a … WebAug 29, 2024 · Investors: Dyne Therapeutics Amy Reilly [email protected] 857-341-1203 Media: Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938. Related Quotes. Symbol Last Price Change % Change ...
WebNX-13. NX-13 is an oral NLRX1 agonist for the treatment of Ulcerative Colitis and Crohn’s Disease. NX-13’s bimodal mechanism of action aims to decrease reactive oxygen … WebDyne Therapeutics General Information. Description. Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
WebMar 20, 2024 · About DYNE-251 and the DELIVER Trial. DYNE-251 is an investigational therapeutic being evaluated in the Phase 1/2 global DELIVER trial, for people living with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The DELIVER clinical trial consists of a 24-week multiple ascending dose (MAD) randomized placebo …
WebSep 6, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938. Related Quotes. Symbol Last Price Change % Change ... movies that take place in swampsWebApr 11, 2024 · A high-level overview of Dyne Therapeutics, Inc. (DYN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and … heath xone:23 mixerWebFeb 18, 2024 · Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Rating) - Oppenheimer issued their FY2024 earnings estimates for Dyne Therapeutics in a report released on Tuesday, February 14th.Oppenheimer analyst F. Brisebois expects that the company will earn ($3.17) per share for the year. Oppenheimer currently has a "Outperform" rating … heath xlWebMay 15, 2024 · May 14, 2024 8:16 PM ET Dyne Therapeutics, Inc. (DYN) SA Transcripts. 135.02K Follower s. The following slide deck was published by Dyne Therapeutics, Inc. … movies that take place in summerWebLandos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. … heathy2heath xone 42 mixerWebJan 18, 2024 · Dyne Therapeutics (DYN-5.97%) saw its shares slump 18.1% on Tuesday. The biotech stock closed on Friday at $9.29 a share, then opened on Tuesday at $7.82, falling to a new 52-week low of $7.61 in ... movies that take place in switzerland